AI assistant
Verona Pharma plc — Director's Dealing 2025
Jun 18, 2025
30667_dirs_2025-06-18_a0033695-6455-49d3-a452-a20734d2a98a.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4/A — Form 4/A
Issuer: Verona Pharma plc (VRNA)
CIK: 0001657312
Period of Report: 2025-05-15
Reporting Person: Fisher Andrew (General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-15 | Ordinary Shares | M | 80000 | $2.0113 | Acquired | 439999 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2025-05-15 | Share Options (Right to Buy) | $2.0113 | M | 80000 | Disposed | 2034-03-31 | Ordinary Shares (80000) | Direct |
Footnotes
F1: This amendment is being filed to correct the Reporting Person's Form 4 filed on May 16, 2025, which contained a typographical error in the price reported.
F2: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F3: The number of securities underlying the option and the exercise price therefor are listed in terms of Ordinary Shares, however, each security is represented by American Depositary Shares, each of which represents eight (8) Ordinary Shares of the Issuer.
F4: The option vested and became exercisable as to 25% on March 4, 2025. The remainder of the shares vested or will vest in 36 equal monthly installments thereafter.